These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15268652)

  • 1. Patients' role in reporting adverse drug reactions.
    van Grootheest K; de Jong-van den Berg L
    Expert Opin Drug Saf; 2004 Jul; 3(4):363-8. PubMed ID: 15268652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Adverse Drug Reactions using Medical Named Entities on Twitter.
    MacKinlay A; Aamer H; Yepes AJ
    AMIA Annu Symp Proc; 2017; 2017():1215-1224. PubMed ID: 29854190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A distributed, collaborative intelligent agent system approach for proactive postmarketing drug safety surveillance.
    Ji Y; Ying H; Farber MS; Yen J; Dews P; Miller RE; Massanari RM
    IEEE Trans Inf Technol Biomed; 2010 May; 14(3):826-37. PubMed ID: 20007038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reporting of fatal adverse drug reactions.
    Liu BA; Knowles SR; Mittmann N; Einarson T; Shear NH
    Can J Clin Pharmacol; 2001; 8(2):84-8. PubMed ID: 11493936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase.
    Strandell J; Caster O; Bate A; Norén N; Edwards IR
    Drug Saf; 2011 Mar; 34(3):253-66. PubMed ID: 21332249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study.
    Schutte T; Tichelaar J; Reumerman MO; van Eekeren R; Rolfes L; van Puijenbroek EP; Richir MC; van Agtmael MA
    Drug Saf; 2017 May; 40(5):409-418. PubMed ID: 28120270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing surveillance of adverse drug reactions: problems and solutions.
    Lortie FM
    CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nurses are increasingly involved in pharmacovigilance in Sweden.
    Ulfvarson J; Mejyr S; Bergman U
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):532-7. PubMed ID: 17072915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.
    Härmark L; van Hunsel F; Grundmark B
    Drug Saf; 2015 Apr; 38(4):337-47. PubMed ID: 25627832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involving the patient in reporting adverse drug reactions.
    Campbell JP; Howie JG
    J R Coll Gen Pract; 1988 Aug; 38(313):370-1. PubMed ID: 3256650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Veterinary pharmacovigilance in India: A need of hour.
    Kumar R; Kalaiselvan V; Verma R; Kaur I; Kumar P; Singh GN
    Indian J Pharmacol; 2017; 49(1):2-3. PubMed ID: 28458414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using a computerized discharge summary data base check box for adverse drug reaction monitoring.
    Schiff GD
    QRB Qual Rev Bull; 1990 Apr; 16(4):149-55. PubMed ID: 2113667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dealing with adverse drug reactions in dentistry. Procedures on encountering adverse drug reactions and goal of the Swiss Pharmacovigilance system].
    Egger SS; Krähenbühl S; Schlienger RG
    Schweiz Monatsschr Zahnmed; 2005; 115(12):1209-18. PubMed ID: 16408825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adverse drug event manager facilitates spontaneous reporting of adverse drug reactions.
    Vinther S; Klarskov P; Borgeskov H; Darsø P; Christophersen AK; Borck B; Christensen C; Hansen MV; Halladin NM; Christensen MB; Harboe KM; Lund M; Jimenez-Solem E
    Dan Med J; 2017 Jan; 64(1):. PubMed ID: 28007050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
    Jose J; Rao PG
    Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions for CAM and conventional drugs detected in a network of physicians certified to prescribe CAM drugs.
    Tabali M; Ostermann T; Jeschke E; Witt CM; Matthes H
    J Manag Care Pharm; 2012; 18(6):427-38. PubMed ID: 22839683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance.
    Golomb BA; McGraw JJ; Evans MA; Dimsdale JE
    Drug Saf; 2007; 30(8):669-75. PubMed ID: 17696579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.